Information Provided By: 
Fly News Breaks for July 12, 2016
SCMP
Jul 12, 2016 | 08:37 EDT
Roth Capital analyst Michael Higgins says Sucampo should be bought on weakness following the company's announcement that it has discontinued the development of its cobiprostone. Given the drug's lack of clinical evidence, the analyst says he had not included it in his models and notes that Sucampo's revenues are driven primarily by its leading asset, Amitiza, which has been approved since 2006 to treat adults with constipation. Higgins reiterates a Buy rating and $29 price target on the shares.
News For SCMP From the Last 2 Days
There are no results for your query SCMP
